Global infectious disease therapeutics market is projected to witness a CAGR of 5.76% during the forecast period 2024–2031, growing from USD 108.09 billion in 2023 to USD 169.15 billion in 2031. Infectious diseases have a significant impact on the global healthcare market, leading to economic, social, and health-related consequences. Tuberculosis accounted for the second highest deaths from infectious disease in 2022 after COVID-19. COVID-19, tuberculosis, HIV/AIDS, and malaria accounted for 1.24 million, 1.13 million, 0.63 million, and 0.62 million deaths respectively. The global healthcare industry is under significant pressure due to infectious diseases, which are caused by various infectious agents such as viruses, viroids, and bacteria. Although advanced diagnosis and treatment options, as well as improvements in hygiene, vaccination, and antimicrobial therapy, have reduced the number of deaths caused by infectious diseases, the rise and re-occurrence of infectious diseases continue to affect global health outcome. The infectious disease therapeutics market is expected to grow significantly over the forecast period due to rising infectious disease occurrences, increased awareness about early infectious disease diagnosis, and increased research and funding activities by various private and government organizations.
For instance, WHO launched a global network to detect and prevent infectious disease threats in 2023. Not only does this initiative provide a platform to connect countries and regions, but it also improves the system for analyzing and collecting samples from around the globe, which will help and improve the public healthcare sector in decision-making and welfare.
Increasing Prevalence and Mortality Rate of Infectious Diseases
The increasing prevalence of infectious diseases is expected to drive the sales of infectious disease therapeutics in developing nations. Furthermore, significant investments in health research and life sciences in emerging countries are facilitating the adoption of advanced technologies, thereby promoting the diagnosis and treatment of infectious diseases. Morbidity and mortality are mainly caused due to infectious diseases. Such diseases are the cause of more than 33% or 52 million annual deaths, globally. Nearly half of the global population is at risk of recurring infectious diseases.
Countries, such as India, South Korea, Brazil, and Mexico, have a high burden of infectious diseases like Hepatitis, HAI, HIV, and influenza. As a result, medical device companies are increasing investments and manufacturing capacities in these countries to meet the demand for diagnostic devices and instruments over the forecast period.
Get Full Access for Report: https://www.marketsandata.com/industry-reports/infectious-disease-therapeutics-market
Viral Therapeutics are Dominating the Market
In 2022, viral therapeutics held the second-largest market share in the infectious disease therapeutics sector. The significant share held by this segment is attributed to the growing prevalence of viral diseases like hepatitis and HIV, the increasing number of clinical trials for new drug launches, and initiatives aimed at enhancing drug adoption. Hepatitis and human papillomavirus patients are increasing at a rapid rate globally. Due to the rapid increase in the prevalence and incidence of infectious diseases, medical device manufacturers are prioritizing innovation and manufacturing capacities.
The World Health Organization’s (WHO) Global Health Sector Strategy on viral hepatitis aims to test and treat a large proportion of individuals with HBV and HCV by 2030. In January 2023, the Serum Institute of India launched ‘CERVAVAC,’ the first Quadrivalent Human Papillomavirus vaccine made in India, in collaboration with DBT, BIRAC, and the Bill and Melinda Gates Foundation. This vaccine is India’s first indigenously developed vaccine for the prevention of cervical cancer. This vaccine is affordable and cost effective and the government of India has taken initiatives to make it accessible for everyone in the country.
Government Initiatives
Governments around the globe have been actively engaged in fostering advancements within the infectious disease therapeutics market through various initiatives. These efforts aim to address emerging health challenges and ensure preparedness for infectious outbreaks. Governments often allocate substantial funding for research and development, supporting pharmaceutical companies and academic institutions with their objective of developing innovative therapeutics. Additionally, regulatory bodies play a crucial role in streamlining the approval process to expedite the availability of new treatments. For instance, in India, the Infectious Disease Biology Program aims to provide solutions to infectious diseases of global concern such as HIV/AIDS, tuberculosis, and vector borne diseases, along with emerging or re-emerging threats like influenza, Japanese Encephalitis, and antibiotic-resistant microbes in terms of therapeutics, diagnostics, and preventive measures. The Program supports R&D projects to achieve the Sustainable Development Goals Target to combat various water-borne diseases, communicable diseases, and hepatitis and end the epidemics of viral diseases like AIDS, TB, and malaria by the year 2030.
Dominance of Molecular Diagnostic Techniques, Especially PCR
Nucleic Acid amplification tests, PCR, are a few molecular diagnostic techniques that are going to be more popular in the coming frame of time. PCR is the most widely used nucleic acid amplification method for pathogen detection and has become an important tool in the early diagnosis of infectious diseases, bacterial infections, GI infections, and sexually transmitted diseases.
Thermo Fisher launched real-time PCR kits for the detection of infectious diseases in India in February 2023. The TaqPath PCR kits provide assurance and consistency for the creation and examination of diagnostic tests for infectious diseases. Genetic risk factor identification, therapy response monitoring, and disease screening are a few patient care practices that can be now carried out using the TaqPath PCR kits developed by Thermo Fisher.
North America Dominates Infectious Disease Therapeutics Market
North America is dominating the infectious diseases therapeutics market due to the increasing prevalence of infectious diseases, improving healthcare infrastructure, the presence of key market players, and rising awareness programs. Government initiatives and their effort towards providing the country with adequate infrastructure and facilities, such as trained professionals, high-end medical devices, and drugs, are creating lucrative market opportunities in the region. Other factors accelerating the market demand in North America includes the growing prevalence of such diseases, favorable reimbursement scenarios, the presence of numerous manufacturers in the U.S., and an increasing number of clinical trials for developing new treatment drugs and devices. According to the Centers for Disease Control and Prevention, in the United States., influenza and pneumonia caused 41,917 deaths in 2022.
Future Market Scenario (2024–2031F)
The future market scenario for treatments for infectious diseases is expected to be dynamic, driven by continued technological development and a greater emphasis on preventive measures. More individualized and efficient treatments are expected by the ongoing development of precision medicine, which is made possible by advancements in genomics and personalized therapies. Novel treatments for infectious diseases are being made possible by developments in immunotherapy and antiviral drugs, which are changing the market landscape. The COVID-19 pandemic has expedited the development, production, and distribution of vaccines, enabling a more responsive approach to newly emerging infectious diseases.
Infectious diseases have been a perpetual challenge for humanity, shaping the course of history and influencing healthcare practices. From ancient plagues to modern pandemics, the battle against infectious agents continues to evolve. In this dynamic landscape, the infectious disease therapeutics market plays a pivotal role, driving innovation, and shaping treatment paradigms. This article delves into the current state and future prospects of this vital sector.
Understanding the Market Dynamics: The infectious disease therapeutics market encompasses a wide array of treatments targeting various pathogens, including bacteria, viruses, fungi, and parasites. Factors such as globalization, urbanization, antimicrobial resistance, and emerging infectious threats contribute to the complexity of this market.
Download Free Sample Report: https://www.marketsandata.com/industry-reports/infectious-disease-therapeutics-market/sample-request
Market Size and Growth Trends: The global infectious disease therapeutics market has experienced significant growth in recent years, driven by several factors:
- Increasing Prevalence: The prevalence of infectious diseases remains high worldwide, with notable examples including HIV/AIDS, tuberculosis, malaria, and hepatitis.
- Technological Advancements: Advances in biotechnology, genomics, and drug discovery have facilitated the development of novel therapeutics with improved efficacy and safety profiles.
- Emerging Infectious Threats: Outbreaks of emerging infectious diseases, such as Ebola, Zika, and COVID-19, have heightened awareness and spurred investment in infectious disease research and development.
- Antimicrobial Resistance: The growing threat of antimicrobial resistance underscores the need for new antibiotics and alternative treatment modalities.
Market Segmentation: The infectious disease therapeutics market can be segmented based on the type of pathogen targeted, including antibacterial, antiviral, antifungal, and antiparasitic agents. Additionally, therapeutics may be classified based on their mechanism of action, such as antibiotics, antiviral drugs, immunomodulators, and vaccines.
Key Players and Competitive Landscape: The market for infectious disease therapeutics is highly competitive, with numerous pharmaceutical companies, biotech firms, and academic institutions engaged in research and development activities. Key players include multinational corporations like Pfizer, GlaxoSmithKline, Merck & Co., and Johnson & Johnson, as well as smaller biotech companies specializing in infectious disease treatments.
Challenges and Opportunities: Despite significant progress, the infectious disease therapeutics market faces several challenges, including regulatory hurdles, clinical trial complexities, and limited access to healthcare in resource-limited settings. However, these challenges also present opportunities for innovation, collaboration, and investment in novel therapeutic approaches.
Future Outlook: Looking ahead, the infectious disease therapeutics market is poised for continued growth, driven by ongoing research efforts, technological advancements, and the emergence of new infectious threats. Key areas of focus include the development of broad-spectrum antiviral drugs, innovative vaccine platforms, and precision medicine approaches tailored to individual patients.
Contact
Mr. Vivek Gupta
5741 Cleveland street,
Suite 120, VA beach, VA, USA 23462
Tel: +1 (757) 343–3258
Email: info@marketsandata.com
Website: https://www.marketsandata.com